Ritonavir [155213-67-5]
R3577
Estimated Purity≥98%
Product group Chemicals
Overview
- SupplierLKT Laboratories
- Product NameRitonavir [155213-67-5]
- Delivery Days Customer7
- CertificationResearch Use Only
- Estimated Purity≥98%
- FormatDMSO to 10 mg/mL, Ethanol to 3 mg/mL, Methanol
- Scientific DescriptionHIV protease inhibitor.; Norvir, A-84538, ABT-538, NSC693184, RTV
- Storage InstructionAmbient
- UNSPSC12352200
References
- Vadlapatla RK, Vadlapudi AD, Pal D, et al. Ritonavir inhibits HIF-1alfa-mediated VEGF expression in retinal pigment epithelial cells in vitro. Eye (Lond). 2013 Nov 8. [Epub ahead of print]. PMID: 24202050. Kao E, Shinohara M, Feng M, et al. Human immunodeficiency virus protease inhibitors modulate Ca2+ homeostasis and potentiate alcoholic stress and injury in mice and primary mouse and human hepatocytes. Hepatology. 2012 Aug;56(2):594-604. PMID: 22407670. Hisatomi T, Nakazawa T, Noda K, et al. HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice. J Clin Invest. 2008 Jun;118(6):2025-38. PMID: 18497877. Grigem S, Fischer-Posovszky P, Debatin KM, et al. The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes. Horm Metab Res. 2005 Oct;37(10):602-9. PMID: 16278782. Riddle TM, Schildmeyer NM, Phan C, et al. The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. J Lipid Res. 2002 Sep;43(9):1458-63. PMID: 12235177. Beach JW. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin Ther. 1998 Jan-Feb;20(1):2-25. PMID: 9522101. Kawakami K, Harada T, Yoshihashi Y, et al. Correlation between glass-forming ability and fragility of pharmaceutical compounds. J Phys Chem B. 2015 Apr 9;119(14):4873-4880. PMID: 25781503.